These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients. Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270 [TBL] [Abstract][Full Text] [Related]
6. Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis. Uhel F; Azzaoui I; Grégoire M; Pangault C; Dulong J; Tadié JM; Gacouin A; Camus C; Cynober L; Fest T; Le Tulzo Y; Roussel M; Tarte K Am J Respir Crit Care Med; 2017 Aug; 196(3):315-327. PubMed ID: 28146645 [TBL] [Abstract][Full Text] [Related]
7. CD1d is a novel cell-surface marker for human monocytic myeloid-derived suppressor cells with T cell suppression activity in peripheral blood after allogeneic hematopoietic stem cell transplantation. An B; Lim JY; Jeong S; Shin DM; Choi EY; Min CK; Hong SH Biochem Biophys Res Commun; 2018 Jan; 495(1):519-525. PubMed ID: 29108995 [TBL] [Abstract][Full Text] [Related]
8. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer. Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521 [TBL] [Abstract][Full Text] [Related]
9. CD33 Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700 [TBL] [Abstract][Full Text] [Related]
10. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential. Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030 [TBL] [Abstract][Full Text] [Related]
11. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. Raychaudhuri B; Rayman P; Huang P; Grabowski M; Hambardzumyan D; Finke JH; Vogelbaum MA J Neurooncol; 2015 Apr; 122(2):293-301. PubMed ID: 25579983 [TBL] [Abstract][Full Text] [Related]
12. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. Kontaki E; Boumpas DT; Tzardi M; Mouzas IA; Papadakis KA; Verginis P Autoimmunity; 2017 May; 50(3):170-181. PubMed ID: 28276713 [TBL] [Abstract][Full Text] [Related]
13. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology]. Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197 [TBL] [Abstract][Full Text] [Related]
14. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice. Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053 [TBL] [Abstract][Full Text] [Related]
15. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. Lee SE; Lim JY; Kim TW; Ryu DB; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK J Immunother Cancer; 2019 Feb; 7(1):35. PubMed ID: 30732646 [TBL] [Abstract][Full Text] [Related]
16. Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients. Utrero-Rico A; Laguna-Goya R; Cano-Romero F; Chivite-Lacaba M; Gonzalez-Cuadrado C; Rodríguez-Sánchez E; Ruiz-Hurtado G; Serrano A; Fernández-Ruiz M; Justo I; González E; Andrés A; Paz-Artal E Transplantation; 2020 Dec; 104(12):2599-2608. PubMed ID: 32068661 [TBL] [Abstract][Full Text] [Related]
17. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365 [TBL] [Abstract][Full Text] [Related]
18. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets. Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893 [No Abstract] [Full Text] [Related]
19. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Azzaoui I; Uhel F; Rossille D; Pangault C; Dulong J; Le Priol J; Lamy T; Houot R; Le Gouill S; Cartron G; Godmer P; Bouabdallah K; Milpied N; Damaj G; Tarte K; Fest T; Roussel M Blood; 2016 Aug; 128(8):1081-92. PubMed ID: 27338100 [TBL] [Abstract][Full Text] [Related]
20. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. Khaled YS; Ammori BJ; Elkord E J Immunol Res; 2014; 2014():879897. PubMed ID: 24741628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]